Summary
EudraCT Number: 2009-015162-57
Sponsor's Protocol Code Number: P06153
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Prematurely Ended
Date on which this record was first entered in the EudraCT database: 2011-03-31
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015162-57/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2009-015162-57
A.3 Full title of the trial: Estudio de extensi칩n de fase 3, de 40 semanas, controlado con tratamiento activo, doble ciego y doble simulaci칩n del preladenant en sujetos con enfermedad de Parkinson de moderada a grave (fase 3; n. de protocolo P06153)
A.4.1 Sponsor's protocol code number: P06153
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Schering-Plough Research Institute, a division of Schering Corporation
B.1.3.4	Country: United States
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: No
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Preladenant
D.3.2 Product code: SCH 420814
D.3.4 Pharmaceutical form: Coated tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Preladenant
D.3.9.1 CAS number: 377727-87-2
D.3.9.2 Current sponsor code: SCH 420814
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: range
D.3.10.3 Concentration number: 2 to 10
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Azilect
D.2.1.1.2 Name of the Marketing Authorisation holder: Lundbeck (Schweiz) AG
D.2.1.2 Country which granted the Marketing Authorisation: Switzerland
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Azilect
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Rasagiline mesylate
D.3.9.1 CAS number: 161735-79-1
D.3.9.3 Other descriptive name: RASAGILINE MESILATE
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Azilect
D.2.1.1.2 Name of the Marketing Authorisation holder: Teva Pharma GmbH
D.2.1.2 Country which granted the Marketing Authorisation: Germany
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Azilect
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Rasagiline mesylate
D.3.9.1 CAS number: 161735-79-1
D.3.9.3 Other descriptive name: RASAGILINE MESILATE
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Coated tablet
D.8.4 Route of administration of the placebo: Oral use
D.8 Placebo: 2
D.8.1 Is a Placebo used in this Trial? Yes
D.8.3 Pharmaceutical form of the placebo: Capsule
D.8.4 Route of administration of the placebo: Oral use

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Enfermedad de Parkinson
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 13.1
E.1.2 Level: PT
E.1.2 Classification code: 10061536
E.1.2 Term: Parkinson's disease
E.1.2 System Organ Class: 10029205 - Nervous system disorders
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Evaluar la seguridad y tolerabilidad a largo plazo del preladenant en sujetos con enfermedad de Parkinson (EP) de moderada a grave.
E.2.2 Secondary objectives of the trial: Caracterizar la eficacia a largo plazo del preladenant en sujetos con EP de moderada a grave.
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: En este ensayo participar치n sujetos adultos con un diagn칩stico al inicio del ensayo original (P04938 o P07037) de enfermedad de Parkinson de moderada a grave con presencia de fluctuaciones motoras que hayan completado el periodo de tratamiento de 12 semanas del ensayo original.Los sujetos deben haber completado el ensayo P04938 o P07037.
Cada sujeto (o su representante legal) debe estar dispuesto a dar su consentimiento informado por escrito para el ensayo P06153 y ser capaz de hacerlo. En el caso de que un sujeto no pueda dar su consentimiento independiente, un representante legal puede dar su consentimiento informado por escrito.
Los sujetos deben poder cumplir los calendarios de dosis y visitas.
Los sujetos deben estar bajo tratamiento con levodopa (L-dopa).
Los sujetos pueden estar recibiendo tratamiento con cualquier otra medicaci칩n complementaria adicional para la EP incluida en la siguiente tabla.
Nota: Los sujetos que 칰nicamente reciben tratamiento con L-dopa pueden incluirse en este ensayo.
(Amantadina, Anticolin칠rgicos, Inhibidores de la dopa descarboxilasa, Agonistas de la dopamina, Entacapona, L-dopa)
Cada sujeto debe presentar resultados de an치lisis cl칤nicos de laboratorio (hematolog칤a, bioqu칤mica y an치lisis de orina) dentro de los l칤mites normales o cl칤nicamente aceptables para el investigador seg칰n se demuestre en los 칰ltimos resultados de an치lisis disponibles del estudio original (P04938 o P07037), y ning칰n resultado se situar치 dentro de los par치metros de exclusi칩n descritos a continuaci칩n en los criterios de exclusi칩n relativos a hallazgos hep치ticos.
No ha habido cambios en el estado serol칩gico o no se han producido hallazgos que justifiquen su determinaci칩n (para citomegalovirus [CMV], virus de Epstein-Barr [VEB] y hepatitis B, C y E).
Cada sujeto debe presentar resultados de una exploraci칩n f칤sica dentro de los l칤mites normales, incluyendo una presi칩n arterial dentro de los l칤mites normales o l칤mites cl칤nicamente aceptables para el investigador y fuera de los par치metros de exclusi칩n descritos a continuaci칩n en los criterios de exclusi칩n para la presi칩n arterial.
Todos los sujetos sexualmente activos o que tengan previsto ser sexualmente activos deben acceder a utilizar un m칠todo anticonceptivo altamente eficaz durante la participaci칩n del sujeto en el estudio y durante las dos semanas posteriores a la 칰ltima dosis del f치rmaco del estudio. Los sujetos de sexo masculino no deben donar esperma en las dos semanas posteriores a la 칰ltima dosis del f치rmaco del estudio. Los datos completos sobre los requisitos anticonceptivos se especifican en la secci칩n 7.7.1.7 del protocolo.
E.4 Principal exclusion criteria: El sujeto no debe haber sido retirado de los ensayos P04938 o P07037 bajo ning칰n concepto.
El sujeto no debe presentar una enfermedad m칠dica inestable grave o en curso (p. ej., cualquier enfermedad card칤aca cl칤nicamente significativa, hipotensi칩n ortost치tica sintom치tica, epilepsia o dependencia de alcohol/drogas).
El sujeto no debe presentar diabetes mal controlada (por ejemplo, HbA1c > 8,5) o una funci칩n renal significativamente anormal (p. ej., creatinina > 2,0 mg/dl) en opini칩n del investigador.
Como continuaci칩n de los criterios de retirada de tipo hep치tico de los estudios originales (P04938 y P07037), cualquier sujeto con valores elevados de alanina aminotransferasa (ALT) aspartato aminotransferasa (AST) o bilirrubina total (BIL-T), seg칰n se demuestre en los resultados del an치lisis m치s reciente de bioqu칤mica en el estudio original, que cumpla uno de los siguientes criterios:
ALT o AST > 8 x LSN.
ALT o AST > 5 x LSN durante m치s de dos semanas.
ALT o AST > 3 x LSN y (BIL-T > 2 x LSN o 칤ndice normalizado internacional [INR] > 1,5 por causa distinta a anticoagulaci칩n) en la misma visita.
ALT o AST > 3 x LSN con aparici칩n de agravaci칩n de la fatiga, n치useas, v칩mitos, dolor o dolor a la palpaci칩n en el cuadrante superior derecho, fiebre, erupci칩n cut치nea y/o eosinofilia (> 5%).
Como continuaci칩n de los criterios de retirada de la presi칩n arterial (PA) de los estudios originales (P04938 y P07037), cualquier sujeto que cumpla los siguientes criterios en la segunda de dos visitas consecutivas separadas por siete d칤as (es decir, el sujeto ya cumple uno de los criterios de PA siete d칤as antes de la visita de selecci칩n del estudio P06153):
PA sist칩lica > o = 180 mm Hg o PA diast칩lica > o = 105 mm Hg, o
Una elevaci칩n de la PA inicial en el estudio original (P04938 o P07037) de la PA sist칩lica >  o = 40 mm Hg o de la PA diast칩lica > o =20 mm Hg.
El sujeto no debe presentar antecedentes de c치ncer primario o recurrente en los cinco 칰ltimos a침os, con la excepci칩n del c치ncer de piel de c칠lulas basales o c칠lulas escamosas adecuadamente tratado, c치ncer cervical in situ o c치ncer de pr칩stata in situ con ant칤geno prost치tico espec칤fico (PSA) normal despu칠s de la resecci칩n.
El sujeto no debe presentar un consumo diario medio de m치s de 180 ml de vino o equivalente.
Medicamentos concomitantes prohibidos: El sujeto no debe recibir tratamiento o iniciar tratamiento con ninguno de los medicamentos enumerados en la siguiente tabla.
El sujeto no debe haber recibido tratamiento con ninguno de los medicamentos incluidos en la siguiente tabla en un periodo menor que el indicado antes del d칤a 1 del estudio P06153.
Nota: Deben seguirse las advertencias y contraindicaciones indicadas en la informaci칩n de prescripci칩n para los medicamentos permitidos (mostrados en los criterios de inclusi칩n).
E.5 End points
E.5.1 Primary end point(s): Los criterios de valoraci칩n de la seguridad est치n relacionados con el objetivo principal del ensayo. Los criterios de valoraci칩n de la eficacia incluir치n los cambios desde el inicio en cada uno de los siguientes elementos:
Puntuaci칩n de la MoCA; Puntuaci칩n del EQ-5D; Puntuaci칩n del PDQ-39; Puntuaci칩n del BDI-II; Puntuaci칩n de la Escala de la Apat칤a; Datos del diario que incluyen los siguientes criterios de valoraci칩n de la eficacia: Media de horas al d칤a en estado off, Media de horas al d칤a en estado on, Media de horas al d칤a en estado on sin discinesias molestas, Media de horas al d칤a en estado on con discinesias molestas, Proporci칩n de tiempo on sin discinesias, Proporci칩n de tiempo on sin discinesias molestas, Proporci칩n de tiempo on con discinesias molestas, Tiempo total medio de sue침o; Puntuaci칩n total del UPDRS en estado on: Puntuaci칩n del UPDRS para las partes 1, 2 y 3 combinadas, Puntuaci칩n del UPDRS para las partes 2 y 3 combinadas, Puntuaciones de las subescalas del UPDRS para las partes 1, 2, 3 y 4, Dominio del temblor del UPDRS, parte 3.
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: No
E.8.1.3 Single blind: No
E.8.1.4 Double blind: Yes
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 5
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 73
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Last Subject Last Visit
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 2
E.8.9.1 In the Member State concerned months: 6
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 2
E.8.9.2 In all countries concerned by the trial months: 6
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 35
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 480
F.4.2.2 In the whole clinical trial: 750

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2011-05-23
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2011-05-12

P. End of Trial
P. End of Trial Status: Prematurely Ended
P. Date of the global end of the trial: 2013-05-23

